First mRNA flu shot approved by FDA bodes well for improving drugs of the future – though a few hurdles remain before mRNA can move beyond vaccines

The Conversation reports the FDA approved the first mRNA flu vaccine on August fifth for adults fifty and older—providing better protection than traditional vaccines. The approval underscores mRNA's rapid momentum since the COVID-19 pandemic demonstrated the technology's speed and flexibility compared to traditional vaccine development. Before mRNA can branch into treating other diseases, though, researchers must solve two key challenges: mRNA degrades quickly in the body—typically within a day—and the manufacturing process produces impurities that trigger unwanted immune responses. Scientists are working to overcome both by modifying mRNA's molecular components and refining production methods, potentially enabling treatments for genetic diseases and conditions requiring sustained effects.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton